Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA1 | Q13131 | 13/20 | 0.80 |
| ▸ | KDR | P35968 | 12/20 | 0.80 |
| ▸ | PRKAA2 | P54646 | 11/20 | 0.80 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.76 |
| ▸ | EGFR | P00533 | 3/20 | 0.72 |
| ▸ | FLT3 | P36888 | 3/20 | 0.72 |
| ▸ | GRK5 | P34947 | 3/20 | 0.72 |
| ▸ | PLK4 | O00444 | 2/20 | 0.72 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.72 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.72 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.72 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.72 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.72 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.72 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.72 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.72 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.72 |
| ▸ | INSR | P06213 | 2/20 | 0.72 |
| ▸ | LCK | P06239 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13755240 | 1.00 | PRKAA1 (0.80) | PRKAA1KDRPRKAA2PDGFRBFGFR1 | |
| SCHEMBL31672467 | 1.00 | PRKAA1 (0.80) | PRKAA1KDRPRKAA2PDGFRBFGFR1 | |
| SCHEMBL16466926 | 0.93 | KDR (0.80) | PRKAA1KDRPRKAA2PDGFRBFGFR1 | |
| SCHEMBL16466924 | 0.93 | KDR (0.80) | PRKAA1KDRPRKAA2PDGFRBFGFR1 | |
| SCHEMBL7678649 | 0.92 | KDR (0.69) | PRKAA1KDRPRKAA2PDGFRBFGFR1 | |
| SCHEMBL29856331 | 0.90 | PRKAA1 (0.84) | PRKAA1KDRPRKAA2PDGFRBFGFR1 | |
| SCHEMBL30685863 | 0.89 | PRKAA1 (0.74) | PRKAA1KDRPRKAA2PDGFRBFGFR1 | |
| SCHEMBL29856676 | 0.89 | KDR (1.00) | PRKAA1KDRPRKAA2PDGFRBFGFR1 | |
| SCHEMBL29856317 | 0.89 | PRKAA1 (1.00) | PRKAA1KDRPRKAA2PDGFRBFGFR1 | |
| SCHEMBL29856520 | 0.89 | PRKAA1 (1.00) | PRKAA1KDRPRKAA2PDGFRBFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101056632-B | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2011-12-07 | — | — | CN | claimed |
| EP-1814545-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-06-10 | — | — | EP | claimed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | claimed |
| EP-1814545-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-08-08 | — | — | EP | claimed |
| WO-2006052936-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-18 | — | — | WO | claimed |
| EP-3246046-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010120387-A1 | OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-10-21 | — | — | WO | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1814545-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-06-10 | — | — | EP | disclosed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| EP-1536783-B1 | SOLID FORMULATIONS COMPRISING AN INDOLINONE COMPOUND | PFIZER ITALIA SRL (IT) | 2008-08-06 | — | — | EP | disclosed |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040063773-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2004-04-01 | — | — | US | disclosed |
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2003-11-20 | — | — | US | disclosed |
| US-6573293-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-03 | — | — | US | disclosed |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN. INC. | 2003-05-29 | — | — | US | disclosed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| CN-1151187-A | Subtilisin 309 variants having decreased absorption and increased hydrolysis | PROCTER & GAMBLE (US) | 1997-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PTGS2, PTGES2, PTGFR | PRKAA1 896/4885KDR 498/4885PRKAA2 612/4885 |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | PRKAA1 56/4885KDR 1081/4885PRKAA2 54/4885 |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, FRK, PTK2B | PRKAA1 237/4885KDR 204/4885PRKAA2 192/4885 |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | PRKAA1 56/4885KDR 1081/4885PRKAA2 54/4885 |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | PRKAA1 881/4885KDR 395/4885PRKAA2 917/4885 |
| US-20040063773-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | PRKAA1 75/4885KDR 1372/4885PRKAA2 99/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | PRKAA1 75/4885KDR 1372/4885PRKAA2 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.